Inogen, Inc
Inogen develops, manufactures, and markets portable oxygen concentrators for patients, physicians, and payors globally. Its concentrators deliver supplemental long-term oxygen therapy to chronic respiratory condition patients. The company offers portable Inogen One devices, stationary At Home units, airway clearance systems, batteries, and accessories. It also rents products directly to patients.
Overview
Strengths
- Price to book ratio (0.99) is lower than the sector mean (13.90).
Weaknesses
- With a depreciation Potential of -80.49%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (9.03) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (2.97%).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data